"10.1371_journal.pone.0103981","plos one","2014-08-06T00:00:00Z","Tadeusz Kolodka; Matthew L Charles; Arvind Raghavan; Ilian A Radichev; Christina Amatya; Jacob Ellefson; Alexei Y Savinov; Abhijeet Nag; Mark S Williams; Mark S Robbins","DiaMedica USA, Inc., Minneapolis, Minnesota, United States of America; Sanford Project/Childrens Health Research Center, Sanford Research, Sioux Falls, South Dakota, United States of America; Invitek, Inc., Hayward, California, United States of America","Conceived and designed the experiments: TK MLC IAR AYS MSW MSR. Performed the experiments: IAR CA JE AN. Analyzed the data: TK MLC AR IAR AYS AN MSW MSR. Contributed reagents/materials/analysis tools: TK MLC AR AYS AN MSW MSR. Wrote the paper: TK MLC AR AYS MSW MSR.","The authors have read the journals policy and have the following conflicts to declare. TK, MLC, MSW and MSR are shareholders of DiaMedica, which funded this study. AR is a consultant for DiaMedica. AN is a shareholder of Invitek, Inc. MSW is an inventor on the patent PCT/CA2010/000413, Tissue kallikrein for the treatment of pancreatic beta cell dysfunction. MLC is an inventor on the patent PCT/CA2013/050395, Formulations of human tissue kallikrein-1 for parenteral delivery and related methods. TK, MSW and MLC are inventors on the patent PCT/CA2013/050425, Human tissue kallikrein 1 glycosylation isoforms. DM199 is currently in clinical trials for the treatment of type 2 diabetes. There are no further relevant patents, products in development or marketed products to declare. These competing interests do not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","08","Tadeusz Kolodka","TK",10,TRUE,6,4,8,6,TRUE,TRUE,FALSE,0,NA,FALSE
